Markets

Prominent Runners: VirnetX Holding Corp (VHC), Viking Therapeutics, Inc. (VKTX)

VirnetX Holding Corp (VHC):

Last Trade:

VirnetX Holding Corp (VHC) ended its previous trading session at $5.8 with the Gain of 13.73%. The company’s market cap is $398.52 Million, and the average volume is $591.51 Million. The 52-Week High range of the stock is $8.75, while the 52-week low range is $1.7. The Price to Sales (P/S) of the stock is 265.68, while P/B (Price to Book) stands at 64.44. When we look at the Volatility of the company, Week Volatility is at 28.44% whereas Month Volatility is at 16.36%.

VirnetX Holding Corp (VHC) analysts on average have given a price target of $2.88 on VHC stock.

According to the Recommendation Trends of the stock polled by Zacks Investment Research for this month, the company has a consensus recommendation of 1 out of the scale from 1 to 5 where 1 stands for Strong Buy and 5 means Strong Sell.

Viking Therapeutics, Inc. (VKTX):

Previous Trade:

Viking Therapeutics, Inc. (VKTX) shares Jumped 14.62% and ended the day at $2.98. Its 52-week high and low range is between $3.12 and $0.88. The company’s outstanding shares are 27.81 Million. The volume of the company in the last trading session was 3.73 Million. The stock has a market cap of 82.87 Million. The Stock shows P/E value of 0 and Forward P/E of 0.

According to Finviz reported data, The SMA20 of the stock is at 54.64%, SMA50 is 108.89 percent, while SMA200 is 125.04%. The stock is currently has its Return on Assets (ROA) value of -91.3 Percent. The Return on Investment and Return on Equity (ROE) values are 0 percent and -152.7 percent, respectively.

The company’s ATR (Average True Range) is 0.26. The Weekly Volatility is 18.73% and the Monthly Volatility is 15.06%.

When we look at the Analyst Recommendations of the stock, the company has 1 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.

Viking Therapeutics, Inc. (VKTX) analysts on average have given a price target of $2.88 on VKTX stock.

Viking Therapeutics, Inc.’s Average Earnings Estimate for the current quarter is $-0.18, according to consensus of 3 analysts. The low EPS estimate is $-0.23, while the high EPS estimate is $-0.14.

Average Revenue Estimate of the company for the current Fiscal Quarter is $0, according to consensus of 2 analysts. The higher end of the revenue estimate is $0 and the lower end is $0.

Leave a Reply

Your email address will not be published. Required fields are marked *